A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. Save

Date Added
October 10th, 2017
PRO Number
Pro00070030
Researcher
Roberto Pisoni

Silhouette
Keywords
Diabetes, Kidney
Summary

If you are an adult with type 2 diabetes mellitus and diabetic kidney disease, you may be eligible to take part in a clinical research study.
The purpose of this study is to find out if an investigational drug called finerenone slows the progression of diabetic kidney disease. Qualified participants will be randomly assigned to take either finerenone by mouth or placebo (inactive pill). Study medication, study visits, blood work and study procedures will be provided free of charge

Institution
MUSC
Recruitment Contact
Lori Spillers
843-792-8166
spillerl@musc.edu

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease Save

Date Added
October 10th, 2017
PRO Number
Pro00069773
Researcher
Roberto Pisoni

Silhouette
Keywords
Diabetes, Kidney
Summary

If you are an adult with type 2 diabetes mellitus and diabetic kidney disease, you may be eligible to take part in a clinical research study.
The purpose of this study is to find out if an investigational drug called finerenone slows the progression of diabetic kidney disease. Qualified participants will be randomly assigned to take either finerenone by mouth or placebo (inactive pill). Study medication, study visits, blood work and study procedures will be provided free of charge.

Institution
MUSC
Recruitment Contact
Lori Spillers
843-792-8166
spillerl@musc.edu

A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease Save

Date Added
June 14th, 2016
PRO Number
Pro00046888
Researcher
Roberto Pisoni

Silhouette
Keywords
Kidney
Summary

If you are an adult with Autosomal Dominant Polycystic Kidney Disease and have previously participated in a study with an investigational drug called tolvaptan, you may be eligible to take part in this clinical research study. The purpose of this study is to evaluate the long-term safety of an investigational drug called tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease. If eligible, you will be provided the investigational drug tolvaptan. Study drug, study visits, blood work and study procedures will be provided free of charge to qualified participants

Institution
MUSC
Recruitment Contact
Lori Spillers
843-792-8166
spillerl@musc.edu

Change_preferences

-- OR --

Create_login